Restless legs syndrome: Pathophysiology and modern management

Postgraduate Medical Journal

Volumn 89, Issue 1053, 2013, Pages 402-410

  Nagandla, Kavitha ^a   De, Somsubhra ^a  

^a MELAKA MANIPAL MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CABERGOLINE; CARBAMAZEPINE; CARBIDOPA; CLONAZEPAM; FERROUS SULFATE; GABAPENTIN; GABAPENTIN ENACARBIL; HEPCIDIN; LEVODOPA; LEVORPHANOL; METHADONE; OPIATE; OREXIN A; PERGOLIDE; PLACEBO; PRAMIPEXOLE; PREGABALIN; ROPINIROLE; ROTIGOTINE; TEMAZEPAM; TRAMADOL; TRIAZOLAM; ZALEPLON; ZOLPIDEM;

CLINICAL FEATURE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONSTIPATION; DISEASE ASSOCIATION; DIZZINESS; DOPAMINERGIC SYSTEM; DRUG DOSE REDUCTION; ELECTROMYOGRAPHY; GENETIC ASSOCIATION; HUMAN; INCIDENCE; INFLAMMATION; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NAUSEA; NAUSEA AND VOMITING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; POLYSOMNOGRAPHY; PREGNANCY; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; RESTLESS LEGS SYNDROME; RETROPERITONEAL FIBROSIS; REVIEW; RISK; SCLEROTHERAPY; SEDATION; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOMNOLENCE; SUICIDAL IDEATION; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT; VALVULAR HEART DISEASE;

DOPAMINE; MANAGEMENT; PATHOPHYSIOLOGY; PREGNANCY; RESTLESS LEGS SYNDROME;

AMINES; ANEMIA; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGONISTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; GENETIC LINKAGE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEUROPEPTIDES; PARESTHESIA; PREGNANCY; PREGNANCY COMPLICATIONS; PREVALENCE; QUALITY OF LIFE; RESTLESS LEGS SYNDROME;

EID: 84879152037     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/postgradmedj-2012-131634     Document Type: Review

References (102)

1. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, et al. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. Eur J Neurol 2012;11:1385-1396.
2. Benes H, Walters AS, Allen RP, et al. Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord 2007;22 (Suppl 18):S401-S408.
3. Garcia-Borreguero D, Stillman P, Benes H, et al. Algorithms for the diagnosis and treatment of restless legs syndrome in primary care. BMC Neurology 2011;11:28.
4. Högl B, Kiechl S, Willeit J, et al. Restless legs syndrome: a community-based study of prevalence, severity, and risk factors. Neurology 2005;64:1920.
5. Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord 2011;26:114.
6. Hening W, Walters AS, Allen RP, et al. Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study. Sleep Med 2004;5:237-246.
7. Hanson M, Honour M, Singleton A, et al. Analysis of familial and sporadic restless legs syndrome in age of onset, gender, and severity features. J Neurol 2004;251:1398-1401.
8. Allen RP, Walters AS, Montplaisir J, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med 2005;165:1286.
9. Tan EK, Seah A, See SJ, et al. Restless legs syndrome in an Asian population: a study in Singapore. Mov Disord 2001;16:577-579.
10. Kim J, Choi C, Shin K, et al. Prevalence of restless legs syndrome and associated factors in the Korean adult population: the Korean Health and Genome Study. Psychiatry Clin Neurosci 2005;59:350-353.
11. Kageyama T, Kabuto M, Nitta H, et al. Prevalence of periodic limb movement-like and restless legs-like symptoms among Japanese adults. Psychiatry Clin Neurosci 2000;54:296-298.
12. Rangarajan S, Rangarajan S, D'Souza GA. Restless legs syndrome in an Indian urban population. Sleep Med 2007;9:88-93.
13. Sforza E, Mathis J, Bassetti CL. Restless legs syndrome: pathophysiology and clinical aspects. SchweizArch Neurol Psychiatr 2003;154:349-357.
14. Poceta JS, Parsons L, Engelland S, et al. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Sleep Med 2009;10:129-133.
15. Kohnen R, Allen RP, Benes H, et al. Assessment of restless legs syndrome- methodological approaches for use in practice and clinical trials. Mov Disord 2008;8:1200-1202.
16. Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorder in adults-an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses. SLEEP 2012;35:1039-1062.
17. Inoue Y. Diagnosis and symptom rating scale of restless legs syndrome. Brain Nerve 2009;5:533-538.
18. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-119.
19. Michaud M, Dumont M, Paquet J, et al. Circadian variation of the effects of immobility on symptoms of restless legs syndrome. Sleep 2005;7:843-846.
20. Bayard M, Avonda T, Wadzinski J. Restless legs syndrome. Am Fam Physician 2008;78:235-240.
21. Oka Y, Ioue Y. Secondary restless legs syndrome. Brain Nerve 2009;61:539-547.
22. Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord 1997;12:61.
23. Ondo WG, Vuong KD, Wang Q. Restless legs syndrome in monozygotic twins: clinical correlates. Neurology 2000;55:1404.
24. Pichler I, Hicks AA, Pramstaller PP. Restless legs syndrome: an update on genetics and future perspectives. Clin Genet 2008;73:297-305.
25. Fan A, Rao SQ. Advances in genetics of restless legs syndrome. Yi Chuan. 2009;31:675-682.
26. Trenkwalder C, Högl B, Winkelmann A. Recent advances in the diagnosis, genetics and treatment of restless legs syndrome. J Neurol. 2009;256:539-553.
27. Yang Q, Li L, Chen Q, et al. Association studies of variants in MEIS1, BTBD9, and MAP2K5/SKOR1 with restless legs syndrome in a US population. Sleep Med 2011;12:800-804.
28. Schormair B, Plag J, Kaffe M, et al. MEIS1 and BTBD9: genetic association with restless leg syndrome in end stage renal disease. J Med Genet 2011;48:462-466.
29. Rye DB, Adler CH, Allen RP, et al. RLS medical bulletin. Rochester, MN: Restless Legs Syndrome Foundation, 2005.
30. Wetter TC, Stiasny K, Winkelmann J, et al. A randomized controlled study of pergolide in patients with restless legs syndrome. Neurology 1999;52:944-950.
31. Ruottinen HM, Partinen M, Hublin C, et al. An FDOPA PET study in patients with periodic limb movement disorder and restless legs syndrome. Neurology 2000;54:502.
32. Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs syndrome: 18F-dopa and 11C-raclopride PET studies. Neurology 1999;52:932.
33. Cervenka S, Pålhagen SE, Comley RA, et al. Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. Brain 2006;129:2017.
34. Eisensehr I, Wetter TC, Linke R, et al. Normal IPT and IBZM SPECT in drug-naive and levodopa-treated idiopathic restless legs syndrome. Neurology 2001;57:1307.
35. Ondo WG. Restless Legs Syndrome. In: Jankovic J, Tolosa E. Parkinson's disease and movement disorders. 5th edn. Philidelphia: Lippincott, Williams, and Wilkins, 2007:409-20.
36. Trenkwalder C, Paulus W, Walters AS. The restless legs syndrome. Lancet Neurol 2005;4:465-475.
37. Earley CJ, Allen RP, Beard JL, et al. Insight into the pathophysiology of restless legs syndrome. J Neurosci Res 2000;62:623-628.
38. Allen RP, Earley CJ. The role of iron in restless legs syndrome. Mov Disord 2007;22:S440-S448.
39. Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology 2000;54:1698-1700.
40. Allen RP, Barker PB, Wehrl F, et al. MRI measurement of brain iron in patients with restless legs syndrome. Neurology 2001;56:263-265.
41. Krieger J, Schroeder C. Iron, brain and restless legs syndrome. Sleep Med Rev 2001;5:277-286.
42. Earley CJ, Heckler D, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. Sleep Med 2004;5:231-235.
43. Kemlink D, Sonka K, Pretl M, et al. Suggestive evidence of erythropoietin level abnormality in patients with sporadic and familial cases of the restless legs syndrome. Neuro endocrinology letters 2007;28:643-646.
44. Allen RP. Race, iron status and restless legs syndrome. Sleep Med 2002;3:467-468.
45. Taheri S, Zeitzer JM, Mignot E. The role of hypocretins (orexins) in sleep regulation and narcolepsy. Annu Rev Neurosci 2002;25:283.
46. Allen RP, Mignot E, Ripley B, et al. Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. Neurology 2002;59:639.
47. Stiasny-Kolster K, Mignot E, Ling L, et al. CSF hypocretin-1 levels in restless legs syndrome. WH Neurology 2003;10:1426-1429.
48. Weinstock LB, Walters AS, Paueksakon P. Restless legs syndrome-theoretical roles of inflammatory and immune mechanisms. Sleep Med Rev 2012;6:341-354.
49. Walters AS, Rye DB. Review of the relationship of restless legs syndrome and periodic limb movements in sleep to hypertension, heart disease, and stroke. Sleep 2009;32:589-597.
50. Winter AC, Schürks M, Glynn RJ, et al. Restless legs syndrome and risk of incident cardiovascular disease in women and men: prospective cohort. BMJ Open 2012;2:e000866.
51. Ferreri F, Rossini PM. Neurophysiological investigations in restless legs syndrome and other disorders of movement during sleep. Sleep Med 2004;4:397-399.
52. Silber MH, Ehrenberg BL, Allen RP, et al. An algorithm for the management of restless legs syndrome. Mayo Clin Proc 2004;79:916.
53. Winkelman JW, Sethi KD, Kushida CA, et al. Efficacy and safety of pramipexole in restless legs syndrome. Neurology 2006;67:1034.
54. Montplaisir J, Fantini ML, Desautels A, et al. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006;13:1306-1311.
55. Bogan R, Fry J, Schmidt M, et al. TREAT RLS US (Therapy with Ropinirole Efficacy and Tolerability in RLS US) Study Group. Ropinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2006;81:17-27.
56. Trenkwalder C, Garcia-Borreguero D, Montagna P, et al. Ropinirole in the treatment of restless legs syndrome: Results from the TREAT RLS 1 study, a 12-week, randomised, placebo-controlled study in 10 European countries. J Neurol Neurosurg Psychiatry 2004;75:92-97.
57. Walters A, Ondo W, Dreykluft T, et al. Ropinirole is effective in the treatment of restless legs syndrome. TREAT RLS 2: A 12-week, double-blind, randomized, parallel-group, placebo-controlled study. Mov Disord 2004;19:1414-1423.
58. Allen R, Becker P, Bogan R, et al. Ropinirole decreases periodic leg movements and improves sleep parameters in patients with restless legs syndrome. Sleep 2004;27:907-914.
59. Paulus W, Trenkwalder C. Less is more: pathophysiology of dopaminergic-therapy-related augmentation in restless legs syndrome. Lancet Neurol. 2006;5:878-886.
60. Teofilo L. Lee-Chiong. Sleep: a comprehensive handbook. USA: John Wiley and Sons, 2006:473-480.
61. Trenkwalder C, Stiasny-Kolster K, Kupsch A, et al. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Mov Disord 2006;21:1404-1410.
62. Garcia-Borreguero D, Grunstein R, Sridhar G, et al. A 52-week open label study of the long-term safety of ropinirole in patients with restless legs syndrome. Sleep Med 2007;8:742-752.
63. Oertel W, Trenkwalder C, Beneš H, et al. Long-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension study. Lancet Neurol 2011;10:710-720.
64. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004;363:1179.
65. Scholz H, Trenkwalder C, Kohnen R, et al. Levodopa for restless legs syndrome. Cochrane Database Syst Rev 2011, Issue 2. Art.: CD005504.
66. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/ levodopa. Sleep 1996;19:205-213.
67. Earley CJ, Allen RP. Pergolide and carbidopa/levodopa treatment of the restless legs syndrome and periodic leg movements in sleep in a consecutive series of patients. Sleep 1996;19:801.
68. Hogl B, Garcia-Borreguero D, Kohnen R, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multi-center study. J Neurol 2010;257:230-237.
69. Saletu M, Anderer P, Saletu-Zyhlarz G, et al. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) Acute placebo controlled sleep laboratory studies with clonazepam. Eur Neuropsychopharmacol 2001;11:153-161.
70. Walters A, Winkelman J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001;16:1105-1109.
71. Silver N, Allen RP, Senerth J, et al. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med 2011;5:440-444.
72. Happe S, Sauter C, Klosch G, et al. The Treatment of restless legs syndrome: gabapentin versus ropinirole in the treatment of idiopathic restless legs syndrome. Neuropsychobiology 2003;48:82-86.
73. Garcia-Borreguero D, Larrosa O, de la Llave Y, et al. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology 2002;59:1573-1579.
74. Kushida CA, Walters AS, Becker P, et al. A randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndrome. Sleep 2009;32:159-168.
75. Walters AS, Ondo WG, Kushida CA, et al. Gabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trial. Clin Neuropharmacol 2009;32:311-320.
76. Lee DO, Ziman MD, Perkins AT, et al. A randomized, double-blind,placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med 2011;7:282-292.
77. Ellenbogen AL, Thein SG, Winslow D, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol 2011;34:8-16.
78. Allen R, Chen C, Soaita A, et al. A randomized, double-blind, 6-week, dose-ranging study of pregabalin in patients with restless legs syndrome. Sleep Med 2010;11:512-519.
79. Garcia-Borreguero D, Crystal chew MD, Allen R, et al. Long-term efficacy and augmentation assessment of a dopamine agonist (pramipexole) compared with an alpha-2-delta ligand (pregabalin) in restless legs syndrome: results of a randomized, double-blinded, placebo-controlled trial. Abstract 001 2012 Emerg Sci Abstr Neurol 2012;79:e87-e91.
80. Wang J, O'Reilly B, Venkataraman R, et al. Efficacy of oral iron in patients with restless legs syndrome and a low-normal ferritin: a randomized, double-blind, placebo-controlled study. Sleep Med 2009;10:973-975.
81. Earley CJ, Horska A, Mohamed MA, et al. A randomized, double-blind, placebo-controlled trial of intravenous iron sucrose in restless legs syndrome. Sleep Med 2009;10:206-211.
82. Grote L, Leissner L, Hedner J, et al. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in the treatment of restless legs syndrome. Mov Disord 2009;24:1445-1452.
83. Bayard M, Avonda T, Wadzinski J. Restless leg syndrome. Am Fam Physician 2008;78:235-240.
84. Goodman JD, Brodie C, Ayida GA. Restless leg syndrome in pregnancy. BMJ 1988;297:1101-1102.
85. Earley CJ, Heckler D, Allen RP. Repeated IV doses of Iron provides effective supplemental treatment of restless leg syndrome. Sleep Med 2005;4:301-305.
86. Manconi M, Govoni V, De Vito A, et al. Pregnancy as a risk factor for restless legs syndrome. Sleep Med 2004;5:305-308.
87. Mucchiut M, Belgrado E, Cutuli D, et al. Pramipexole-treated Parkinson's disease during pregnancy. Mov Disord 2004;19:1114-1115.
88. Scott M, Chowdhury M. Pregnancy in Parkinson's disease: unique case report and review of the literature. Mov Disord 2005;20:1078-1079.
89. Walters AS, Winkelmann J, Trenkwalder C, et al. Long-term follow-up on restless legs syndrome patients treated with opioids. Mov Disord 2001;16:1105-1109.
90. Dolovich LR, Addis A, Vaillancourt JM, et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998;317:839-843.
91. Saletu M, Anderer P, Saletu-Zyhlarz G, et al. Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): acute placebo-controlled sleep laboratory studies with clonazepam. Eur Neuropsychopharmacol 2001;11:153-161.
92. Telstad W, Sørensen O, Larsen S, et al. Treatment of the restless legs syndrome with carbamazepine: a double blind study. BMJ 1984;288:444-446.
93. Montouris G. Gabapentin exposure in human pregnancy: results from the Gabapentin Pregnancy Registry. Epilepsy Behav 2003;4:310-317.
94. Miri S, Vahdat M, Sariri E, et al. A comparative study of idiopathic and secondary restless legs syndrome in pregnancy [abstract]. Mov Disord 2012;27:1222.
95. Saudi J. Restless legs syndrome in patients on hemodialysis. Kidney Dis Transpl 2011;22:368-372.
96. Kavanagh D, Siddiqui S, Geddes CC. Restless legs syndrome in patients on dialysis. Am J Kidney Dis 2004;43:763.
97. Thorpe ML, Morris CD, Bagby SP. A crossover study of gabapentin in treatment of restless legs syndrome among hemodialysis patients. Am J Kidney Dis 2001;38:104-108.
98. Lee JE, Shin HW, Kim KS, et al. Factors contributing to the development of restless legs syndrome in patients with Parkinson disease. Mov Disord 2009;24:579.
99. Peralta CM, Frauscher B, Seppi K, et al. Restless legs syndrome in Parkinson's disease. Mov Disord 2009;24:2076.
100. Kanter AH. The effect of sclerotherapy on restless legs syndrome. Dermatol Surg 1995;21:328.
101. Poynard T, Valterio C. Meta-analysis of hydroxyethylrutosides in the treatment of chronic venous insufficiency. Vasa 1994;23:244.
102. Konofal E, Cortese S, Marchand M, et al. Impact of restless legs syndrome and iron deficiency on attention-deficit/hyperactivity disorder in children. Sleep Med 2007;8:711-715.